<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 27 May 2021 07:37:50 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>PCSK9的无限进化</title><link>https://mp.weixin.qq.com/s/0ZYsgpixWYIYSvpqReDp2A</link><description></description><content:encoded><![CDATA[PCSK9的无限进化]]></content:encoded><pubDate>Thu, 27 May 2021 06:42:45 +0800</pubDate></item><item><title>JAMA：国药新冠疫苗三期临床数据</title><link>https://mp.weixin.qq.com/s/-UPMWPGXoiQuwK_vrk7bzg</link><description></description><content:encoded><![CDATA[JAMA：国药新冠疫苗三期临床数据]]></content:encoded><pubDate>Thu, 27 May 2021 06:42:45 +0800</pubDate></item><item><title>CCR1抑制剂阻止肿瘤转移</title><link>https://mp.weixin.qq.com/s/enjAwMO8IhFkGLj0fsKv5g</link><description></description><content:encoded><![CDATA[CCR1抑制剂阻止肿瘤转移]]></content:encoded><pubDate>Thu, 27 May 2021 06:42:45 +0800</pubDate></item><item><title>默克推出新型LNP产品</title><link>https://mp.weixin.qq.com/s/vWbo_tx75LMZR0VVRJwL_g</link><description></description><content:encoded><![CDATA[默克推出新型LNP产品]]></content:encoded><pubDate>Thu, 27 May 2021 06:42:45 +0800</pubDate></item><item><title>FDA：双特异性抗体研发指南</title><link>https://mp.weixin.qq.com/s/DQ1offhwIny4TeiLUKXHXw</link><description></description><content:encoded><![CDATA[FDA：双特异性抗体研发指南]]></content:encoded><pubDate>Wed, 26 May 2021 09:26:33 +0800</pubDate></item><item><title>IL-10逆转终末衰竭CD8 T细胞，助力CAR-T攻克实体瘤</title><link>https://mp.weixin.qq.com/s/gAD5tTLq68vHEa8q0mUfSA</link><description></description><content:encoded><![CDATA[IL-10逆转终末衰竭CD8 T细胞，助力CAR-T攻克实体瘤]]></content:encoded><pubDate>Wed, 26 May 2021 09:26:33 +0800</pubDate></item><item><title>TG Therapeutics三代CD20抗体递交FDA上市申请</title><link>https://mp.weixin.qq.com/s/pWgTi4Im1jOhg7kVY6cQSQ</link><description></description><content:encoded><![CDATA[TG Therapeutics三代CD20抗体递交FDA上市申请]]></content:encoded><pubDate>Wed, 26 May 2021 09:26:33 +0800</pubDate></item><item><title>泰诺麦博申报RSV中和抗体</title><link>https://mp.weixin.qq.com/s/koFTKPKbzgCafE0EZYCo-A</link><description></description><content:encoded><![CDATA[泰诺麦博申报RSV中和抗体]]></content:encoded><pubDate>Wed, 26 May 2021 09:26:33 +0800</pubDate></item><item><title>中国GLP-1市场进入爆炸式增长阶段</title><link>https://mp.weixin.qq.com/s/ohjU1nuyiYU5ZAxHLjd2Kw</link><description></description><content:encoded><![CDATA[中国GLP-1市场进入爆炸式增长阶段]]></content:encoded><pubDate>Wed, 26 May 2021 09:26:33 +0800</pubDate></item><item><title>FGF19类似物2b期临床失败，NGM股价腰斩</title><link>https://mp.weixin.qq.com/s/lkV_tsj9H7T-HMAa5U0RRA</link><description></description><content:encoded><![CDATA[FGF19类似物2b期临床失败，NGM股价腰斩]]></content:encoded><pubDate>Tue, 25 May 2021 06:04:05 +0800</pubDate></item><item><title>微小RNA疗法脱颖而出：ABX464治疗溃疡性结肠炎2b期临床成功</title><link>https://mp.weixin.qq.com/s/YXHwkL14Y8TvnpLPiIu52g</link><description></description><content:encoded><![CDATA[微小RNA疗法脱颖而出：ABX464治疗溃疡性结肠炎2b期临床成功]]></content:encoded><pubDate>Tue, 25 May 2021 06:04:05 +0800</pubDate></item><item><title>多发性骨髓瘤新靶点：强生GPRC5D/CD3双抗早期临床数据优异</title><link>https://mp.weixin.qq.com/s/7a6JPnekxOI12h0cGcuISg</link><description></description><content:encoded><![CDATA[多发性骨髓瘤新靶点：强生GPRC5D/CD3双抗早期临床数据优异]]></content:encoded><pubDate>Tue, 25 May 2021 06:04:05 +0800</pubDate></item><item><title>首个ADC类似药印度上市，价格降低80%</title><link>https://mp.weixin.qq.com/s/FgDxEG6tAZMkknpYFgKiuw</link><description></description><content:encoded><![CDATA[首个ADC类似药印度上市，价格降低80%]]></content:encoded><pubDate>Tue, 25 May 2021 06:04:05 +0800</pubDate></item><item><title>武田TAK-788中国申报上市，拟优先审评</title><link>https://mp.weixin.qq.com/s/enxZpB8q_4iuervamPvTYw</link><description></description><content:encoded><![CDATA[武田TAK-788中国申报上市，拟优先审评]]></content:encoded><pubDate>Tue, 25 May 2021 06:04:05 +0800</pubDate></item><item><title>康方生物PD-1递交美国上市申请：入选RTOR，比优先审评更快</title><link>https://mp.weixin.qq.com/s/C9ozYU78Ty9MFvwlrXnL2w</link><description></description><content:encoded><![CDATA[康方生物PD-1递交美国上市申请：入选RTOR，比优先审评更快]]></content:encoded><pubDate>Mon, 24 May 2021 08:54:37 +0800</pubDate></item><item><title>FDA批准第3款双抗：强生EGFR/cMET</title><link>https://mp.weixin.qq.com/s/rnuKGyx9BtRxpvPcHeMLNA</link><description></description><content:encoded><![CDATA[FDA批准第3款双抗：强生EGFR/cMET]]></content:encoded><pubDate>Sat, 22 May 2021 07:13:38 +0800</pubDate></item><item><title>HER2：新时代的研发竞争</title><link>https://mp.weixin.qq.com/s/pKmyzfo4ASi22olDNudMBg</link><description></description><content:encoded><![CDATA[HER2：新时代的研发竞争]]></content:encoded><pubDate>Fri, 21 May 2021 13:23:06 +0800</pubDate></item><item><title>激酶抑制剂二十年</title><link>https://mp.weixin.qq.com/s/VkZnyowv0dlQQHw84iXQUg</link><description></description><content:encoded><![CDATA[激酶抑制剂二十年]]></content:encoded><pubDate>Fri, 21 May 2021 13:23:06 +0800</pubDate></item><item><title>RAS靶向治疗研发格局</title><link>https://mp.weixin.qq.com/s/ecLcEwhDB7nt34aSj_Hzwg</link><description></description><content:encoded><![CDATA[RAS靶向治疗研发格局]]></content:encoded><pubDate>Fri, 21 May 2021 13:23:06 +0800</pubDate></item><item><title>CRS：细胞因子风暴</title><link>https://mp.weixin.qq.com/s/aWsN3EQ5-Gr1g1zs1z2KzA</link><description></description><content:encoded><![CDATA[CRS：细胞因子风暴]]></content:encoded><pubDate>Fri, 21 May 2021 13:23:06 +0800</pubDate></item></channel></rss>